Verastem, Inc.

The US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti

Verastem is readying a commercial drug launch after receiving US Food and Drug Administration approval for the novel-novel drug combination Avmapki Fakzynja (avutometinib/defactinib) for a rare type o

Biohaven’s stock price closed down 15.2% at $19.84 on 25 April on the news that the company withdrew its application for European Medicines Agency approval of troriluzole in the treatment of spinocere

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp